scott d. pegan, ph.d. - profiles.ucr.edu

Scott D. Pegan, Ph.D. Curriculum Vitae

August 2021

1

PERSONAL INFORMATION Work Address: Scott D. Pegan, Ph.D. Professor Division of Biomedical Sciences School of Medicine University of California Riverside 205 SOM Research Building 900 University Avenue Riverside, CA 92521-0001 [email protected] PROFESSIONAL HIGHLIGHTS Employment History University of Georgia (2014-Present) University of Denver (2009-2014) University of Illinois at Chicago (2006-2009) United States Army Reserve (1995-Present) Research Experience

• Developing vaccine and small molecule therapeutic strategies for Crimean Congo Hemorrhagic Fever, SARS-CoV-2, as well as other nairoviruses and coronaviruses

• Developing small molecule and biologic therapeutic strategies for nerve agent poisoning • Awarded 22 grants and contracts from multiple foundations, state and federal agencies to include DoD,

NIH, USDA, and National Pork Board • Authored 50 scientific publications, plus U.S. and International patents on 8 discoveries • Identified preclinical candidates for Tuberculosis and Severe Acute Respiratory Syndrome 1/2 • ~$6.1 M in grants and contracts as Principal Investigator (and ~$8.9 M total overall) • Invited speaker at numerous regional, national, and international forums on therapeutic discovery • Science and Technology Advisor to U.S. Army Research Laboratories and Institutes • Director of a university level Center for Drug Discovery supporting multiple UGA Colleges • Member of state, federal and national review panels (DTRA, CDMRP, USDA, British MRC, CUNY)

Teaching Experience • Taught 93 courses (35 lecture-based offerings); student evaluations consistently in the top 20%. • Department level leader with a focus on academic programs, recruitment, and alt. finance approval • Developed 7 courses and multiple degree programs, • Well versed in online and hybrid pedagogies • Received competitive University-wide Online Course Development Grant • Recognized by UGA as an Outstanding Teacher in the College of Pharmacy 2020 • Grew and led an undergraduate, university level, Office of Experiential Learning

Other Leadership and Service Highlights • Chair, Faculty Council, University System of Georgia • Chair, Executive Committee, University Council, University of Georgia • Trustee of the University of Georgia Foundation, which raised >$230 M in 2017-18 • Member, Board of Directors of the University of Georgia Alumni Association • Chair, Self-Study Planning and Organization Committee, Pharmacy Accreditation • Member of University-wide Comprehensive Administration Review Working Committee • Academic fund raising for laboratories, centers, colleges/schools, academic units, universities • Member, Strategic Plan Review and Revision Task Force, College of Pharmacy • Member of faculty and staff personnel committees (hiring, pre-tenure, tenure, post-tenure)

Scott D. Pegan, Ph.D.

2

EDUCATION 2006 – 2008 Postdoctoral Research Fellow, Advisor: Dr. Andrew Mesecar, Center for Pharmaceutical

Biotechnology, University of Illinois, Chicago, IL, USA 2006 – 2006 Postdoctoral Research Fellow, Advisor: Dr. Senyon Choe, Salk Institute for Biological Studies, La

Jolla, USA 2006 Ph.D. Chemistry, Advisor: Dr. Senyon Choe. Dissertation: Molecular Gating Dynamics of the

Cytoplasmic Domains Of Inwardly Rectifying Potassium (Kir) Channels, University of California, San Diego, USA.

2002 M.Sc. Chemistry, Advisor: Dr. Senyon Choe. University of California, San Diego, USA. 2000 B.Sc. Biochemistry and Molecular Biology (HONS), University of California, Santa Barbara, USA.

ACADEMIC RANK University of Georgia (2014-Present) 2021 – Present Professor, Division of Biomedical Sciences, School of Medicine, University of California

Riverside, CA, USA. 2020 – 2021 Professor, Department of Pharmaceutical and Biomedical Sciences, R.C. Wilson College of

Pharmacy, University of Georgia, Athens, GA, USA. 2021 – Present Affiliated Faculty, Interdisciplinary Toxicology Program, University of Georgia, Athens, GA,

USA. 2014 – 2020 Associate Professor, Department of Pharmaceutical and Biomedical Sciences, R.C. Wilson

College of Pharmacy, University of Georgia, Athens, GA, USA (Tenured 2016) University of Denver (2009-2014) 2011 – 2014 Assistant Professor, Eleanor Roosevelt Institute, University of Denver, CO, USA 2009 – 2014 Assistant Professor, Department of Chemistry & Biochemistry, University of Denver, CO, USA University of Illinois at Chicago (2009-2009) 2009 – 2009 Research Assistant Professor, Department of Medicinal Chemistry, College of Pharmacy,

University of Illinois, Chicago, IL, USA

PUBLICATIONS Peer-Reviewed Publications

1. Nejat R, Sadr AS, Freitas BT, Crabtree J, Tripp RA, Pegan SD, Najafi D., Losartan shows prophylactic and cell surviving effects in cell culture study infected with SARS-CoV2, J. of Pharmacy & Pharmaceutical Sci. J Pharm Pharm Sci. 2021;24:390-399. PMID: 34319871

2. Durie IA, Dzimianski J, Daczkowski C, McGuire J, Faaberg K, Pegan SD., Structural Insights into the interactions of papain-like protease 2 from alphacoronavirus porcine epidemic diarrhea virus and ubiquitin, Acta Crystallogr D Struct Biol. 2021 Jul 1;77(Pt 7):943-953. PMID: 34196620

3. Reynolds ND, Aceves NM, Compton JR, Freitas BT, Pegan SD, Doctor K, Wu FY, Hu X, Legler PM., Extracting COVID-19 Symptoms Directly from the SARS-CoV-2 Viral Genome, ACS Infect Dis. 2021 Jun 11;7(6):1483-1502. PMID: 34019767

4. McGuire J, Bester SM, Guelta MA, Cheung J, Langley C, Winemiller M, Bae SY, Funk V, Myslinski J, Pegan SD, Height J., Structural and biochemical insights into the inhibition of human acetylcholinesterase by G-series nerve agents and subsequent reactivation by HI-6, Chem Res Toxicol. 2021 Feb 4. PMID: 33538594

5. Baker CA, Bester SM, Kirkpatrick MG, Boeri MV, Kastern S, Freitas BT, Pegan SD, Otto TC., Engineering improved stereoselectivity within Brevundimonas diminuta organophosphorus hydrolase for nerve agents. (Unclassified Title), Journal of Chemical and Biological Defense. 2021 2: 63-78.

6. Dzimianski JV, Mace S, Williams IL, Freitas BT, Pegan SD., Flipping Hazara virus OTU substrate preference through structure-based mutagenesis, Acta Crystallogr D Struct Biol. 2020 Nov 1;76(Pt 11):1114-1123. PMID: 33135682


3

7. Freitas BT, Durie IA, Murray J, Longo JE, Miller HC, Crich D, Hogan RJ, Tripp RA, Pegan SD., Characterization and noncovalent inhibition of the deubiquitinase and deISGylase activity of SARS-COV-2 (COVID-19) papain-like protease, 2020 May 17 epub ACS Infect Dis. 2020 Aug 14;6(8):2099-2109 PMID: 32428392 [Selected for Featured Article/Cover]

8. Freitas BT, Scholte FEM, Bergeron E, Pegan SD., How ISG15 Combats Viral Infection, Virus Res. 2020 Sep;286:198036 epub May 31 PMID: 32492472

9. Dhanju S, Upadhyaya K, Rice CA, Pegan SD, Media J, Valeriote FA, Crich D., Synthesis, Cytotoxicity and Genotoxicity of 10-Aza-9-oxakalkitoxin, An N,N,O-Trisubstituted Hydroxylamine Analog of a Marine Natural Product., J Am Chem Soc. 2020 May 20;142(20):9147-9151. PMID: 32364709

10. Dzimianski JV, Williams IL, Langley C, Freitas BT, Scholte FEM, Spengler JR, Bergeron E, Pegan SD., Determining the molecular drivers of species-specific interferon-stimulated gene product 15 interactions with nairovirus ovarian tumor domain proteases, PLoS One 2019 Dec 23;14(12)

11. Scholte FEM, Hua BL, Spengler JR, Dzimianski JV, Coleman-McCray JD, Welch SR, McMullan LK, Nichol ST, Pegan SD, Spiropoulou CF, Bergeron E., Stable Occupancy of the Crimean-Congo Hemorrhagic Fever Virus-Encoded Deubiquitinase Blocks Viral Infection, mBio 2019 Jul 23;10(4), PMID: 31337717 [Selected as the Editor’s Choice for the issue]

12. Scott G, Yau C, Becker B, Khateeb S, Jensen M, Hann B, Cowen B, Pegan SD, and Benz C., Targeting mitochondrial proline dehydrogenase with a suicide inhibitor to exploit synthetic lethal interactions with p53 upregulation and glutaminase inhibition, Mol Cancer Ther 2019 Aug;18(8):1374-1385

13. Bester SM, Adipietro KA, Funk VL, Myslinski J, Keul ND, Cheung J, Wilder PT, Wood ZA, Weber DJ, Height JJ and Pegan SD., The structural and biochemical impact of monomerizing human acetylcholinesterase, Protein Sci. 2019 Apr 16., PMID: 30993792 [Selected for Featured Article/Cover]

14. Scholte FEM, Spengler JR, Welch SR, Harmon JR, Coleman-McCray C, Freitas B, Kainulainen M, Pegan SD, Nichol ST, Bergeron E, Spiropoulou CF., Single-dose replicon particle vaccine provides complete protection against Crimean-Congo hemorrhagic fever virus, Emerg Microbes Infect. 2019;8(1):575-578 PMID: 30947619

15. Hsu F, McGuire J, Anderson DR, Bester SM, Height J, Pegan SD, Walz AJ., Revisiting the synthesis and molecular properties of broad-spectrum nerve agent reactivator HLö 7 dimethanesulfonate, ACS Med Chem. Lett. 2019 Mar 28 ;10(5):761-766. PMID: 31097996

16. Dzimianski JV, Scholte FEM, Bergeron E, Pegan SD., ISG15: it’s complicated, , J Mol Biol. 2019 Mar 16; pii: S0022-2836(19)30136-6. (Invited Review to SI Pathogenesis) PMID: 30890331

17. Dzimianski JV, Beldon B, Daczkowski CM, Goodwin OY, Scholte FEM, Bergeron E, Pegan SD., Probing the impact of nairovirus genomic diversity on viral ovarian tumor domain protease (vOTU) structure and substrate preference, PLoS Pathog. 2019 Jan 10;15(1) PMID:30629698

18. Langley C, Goodwin O, Dzimianski JV, Daczkowski CM, Pegan SD., Structure of ISG15 from the bat species Myotis davidii and the impact of interdomain ISG15 interactions on viral protein engagement. Acta Crystallogr D Biol Crystallogr. Acta Crystallogr D Struct Biol. 2019 Jan 1;75(Pt 1):21-31 PMID:30644842

19. Bester SM, Guelta MA, Cheung J, Winemueller M, Bae SY, Myslinski J, Pegan SD, Height J., Structural insights of stereo specific inhibition of human acetylcholinesterase by VX and subsequent reactivation by HI-6, Chemical Research Toxicology 2018 Nov 21 PMID: 30462502 [Selected for Featured Article/Cover]

20. Bester SM and Daczkowski C, Faaberg K, Pegan SD., Insights into the Porcine Reproductive and Respiratory Syndrome Virus Viral Ovarian Tumor Domain Protease Specificity for Ubiquitin and Interferon Stimulated Gene Product 15, ACS Infect Dis. 2018 Jun 12. PMID: 29856201

21. Kim S, Alsaidn OA, Goodwin O, Li Q, Han Z, Bai A, Ablers T, Beharry Z, Zheng G, Norris JS, Szulc ZM, Alicja Bielawska, Lebedyeva I, Pegan SD, Cai H., Blocking Myristoylation of Src Inhibits Its Kinase Activity and Suppresses Prostate Cancer Progression., Cancer Res. 2017 Oct 16. PMID: 29038344

22. Daczkowski CM, Goodwin O, Dzimianski JV, Farhat JJ, Pegan SD., Structurally guided removal of deISGylase biochemical activity from papain-Like protease originating from the Middle East Respiratory Syndrome Virus, J Virol. 2017 Nov 14;91(23) Epub: 2017 Sep 20. PMID: 28931677


4

23. Scholte FEM, Zivec M, Dzimianski JV, Deaton M, Spengler SR, Welch SR, Nichol ST, Pegan SD, Spiropoulou CF, Bergeron E., Crimean-Congo Hemorrhagic Fever Virus Suppresses Innate Immune Responses via a Ubiquitin and ISG15 Specific Protease. Cell Rep. 2017 Sep 5;20(10):2396-2407. PMID: 28877473

24. Daczkowski CM, Dzimianski JV, Clasman JR, Goodwin O, Mesecar AD, Pegan SD., Structural insights into the interaction of coronavirus papain-like proteases and interferon-stimulated gene product 15 from different species. J Mol Biol. 2017 Apr 21. PMID: 28438633

25. Deaton MK, Dzimianski JV, Daczkowski CM, Whitney GK, Mank NJ, Parham MM, Bergeron E, Pegan SD., Biochemical and structural insights into nairoviral deISGylases preference for interferon-stimulated-gene-product 15 originating from certain species. J Virol. 2016 Jul 13 PMID: 27412597. [Selected as a featured article for its issue]

26. Ziverc M, Metcalfe MG, Albarino CG, Khristova ML, Guererro L, Pegan SD, Spiropoulou CF, Bergeron E., Crimean-Congo hemorrhagic fever virus-like particle system for rapid testing of protein compatibility and antivirals, PLoS Negl Trop Dis. 2015 Dec 1;9(12) PMID: 26625182

27. Daczkowski CM, Pegan SD, Harvey SP. Engineering the Organophosphorus Acid Anhydrolase Enzyme for Increased Catalytic Efficiency and Broadened Stereospecificity on Russian VX, Biochemistry. 2015 Oct 6. PMID:26418828

28. Eisenmesser EZ, Capodagli GC, Armstrong G, Holliday MJ, Isern NG, Zhang F, and Pegan SD., Inherent dynamics within the Crimean-Congo Hemorrhagic fever virus protease are localized to the same region as substrate interactions, Protein Sci. 2015 Jan 6. PMID: 25564798.

29. Capodagli GC, Lee SA, Boehm KJ, Brady KM, Pegan SD., Structural and Functional Characterization of Methicillin-Resistant Staphylococcus aureus's Class IIb Fructose 1,6-Bisphosphate Aldolase. Biochemistry. 2014 Dec 9; 53(48):7604-14. Epub 2014 Nov 21. PMID: 25390935.

30. Zhai X, Go MK, O'Donoghue AC, Amyes TL, Pegan SD., Wang Y, Loria JP, Mesecar AD, Richard JP., Enzyme architecture: the effect of replacement and deletion mutations of loop 6 on catalysis by triosephosphate isomerase. Biochemistry. 2014 Jun 3;53(21):3486-501. Epub 2014 May 22. PMID: 24825099.

31. Deaton MK, Spear A, Faaberg KS, Pegan SD., The vOTU domain of highly-pathogenic porcine reproductive and respiratory syndrome virus displays a differential substrate preference, Virology 2014 Apr. vol. 454–455: 247–253. PMID: 24725951.

32. Capodagli GC, Sedhom WG, Jackson S, Ahrendt KA, Pegan SD., A noncompetitive inhibitor for M. tuberculosis’s class IIa fructose 1,6-bisphosphate aldolase. Biochemistry, 2014 Jan 14; 53(1):202-13., Epub ahead of print on 2013 Dec 24. PMID: 24325645.

33. Capodagli GC, Deaton MK, Baker EA, Lumpkin RJ, Pegan SD., Diversity of ubiquitin and ISG15 specificity amongst nairoviruses’ viral ovarian tumor domain proteases. J Virol. 2013, Apr vol. 87 no. 7 3815-3827, Epub ahead of print on 2013 Jan 23. PMID: 23345508. [Selected as a featured article for its issue]

34. Pegan SD, Rukseree K, Capodagli GC, Baker EA, Krasnykh O, Franzblau SG, Mesecar AD., Active site loop dynamics of a class IIa fructose 1,6-bisphosphate aldolase from M. tuberculosis. Biochemistry 2013 Feb 5;52(5):912-25., Epub ahead of print on 2013 Jan 8. PMID: 23298222.

35. Ray SP, Deaton MK, Capodagli GC, Calkins LAF, Sawle L, Ghosh K, Patterson D, Pegan SD., Structural and Biochemical Characterization of Human Adenylosuccinate Lyase (ADSL) and the R303C ADSL Deficiency Associated Mutation. Biochemistry. 2012 Aug 21;51(33):6701-13. PMID: 22812634.

36. Connor SE, Capodagli GC, Deaton MK, Pegan SD., Structural and functional characterization of Mycobacterium tuberculosis triosephosphate isomerase. Acta Crystallogr D Biol Crystallogr. 2011 Dec;67(Pt 12):1017-22. PMID: 22120738

37. Park SK, Pegan SD, Mesecar AD, Jungbauer LM, Ladu MJ, Liebman SW., Development and validation of a yeast high-throughput screen for inhibitors of Ab42 oligomerization. Dis Model Mech. 2011 Nov;4(6):822-31. PMID: 21810907.

38. Pegan SD, Sturdy M, Ferry G, Delagrange P, Boutin JA, Mesecar AD., X-ray Structural studies of quinone reductase 2 nanomolar range inhibitors. Protein Sci. 2011 Jul;20(7):1182-95. PMID: 21538647. PMC3149192


5

39. Capodagli GC, McKercher MA, Baker EA, Masters EM, Brunzelle JS, Pegan SD., Structural analysis of a viral ovarian tumor domain protease from the Crimean-Congo Hemorrhagic Fever virus in complex with covalently bonded ubiquitin. J Virol. 2011 Apr;85(7):3621-30.

40. Burks EA, Fleming CD, Mesecar AD, Whitman CP, Pegan SD., Kinetic and structural characterization of a heterohexamer 4-oxalocrotonate tautomerase from Chloroflexus aurantiacus J-10-fl: implications for functional and structural diversity in the tautomerase superfamily. Biochemistry. 2010 Jun 22;49(24):5016-27. PMID: 21538647. [Featured Article/Cover]

41. Yang JH, Kondratyuk TP, Marler LE, Qiu X, Choi Y, Cao H, Yu R, Sturdy M, Pegan S, Liu Y, Wang L Q, Mesecar AD, Breemen RB, Pezzuto JM, Fong HH, Chen YG, Zhang HJ., Isolation and evaluation of kaempferol glycosides from the fern Neocheiropteris palmatopedata. Phytochemistry. 2010 Apr;71(5-6):641-7. PMID: 20100622.

42. Pegan SD, Tian Y, Sershon V, Mesecar AD., A universal, fully automated high throughput screening assay for pyrophosphate and phosphate release from enzymatic reactions. Comb Chem High Throughput Screen. 2010 Jan;13(1):27-38. PMID: 20201823 [Featured Article/Cover]

43. Mo S, Krunic A, Pegan SD, Franzblau SG, Orjala J., An antimicrobial guanidine-bearing sesterterpene from the cultured cyanobacterium Scytonema sp. J Nat Prod. (2009) Nov;72(11):2043-5. PMID: 19888742. PMC2988765

44. Guo S, Tipparaju SK, Pegan SD, Wan B, Mo S, Orjala J, Mesecar AD, Franzblau SG, Kozikowski AP., Natural product leads for drug discovery: isolation, synthesis and biological evaluation of 6-cyano-5-methoxyindolo[2,3-a]carbazole based ligands as antibacterial agents. Bioorg Med Chem. 2009 Oct 15;17(20):7126-30. PMID: 19783449. PMC2983099

45. Maiti A, Reddy PV, Sturdy M, Marler L, Pegan SD, Mesecar AD, Pezzuto JM, Cushman M., Synthesis of casimiroin and optimization of its quinone reductase 2 and aromatase inhibitory activities. J Med Chem. 2009 Apr 9;52(7):1873-84. PMID: 19265439. PMC2673050

46. Pegan SD, Rukseree K, Franzblau SG, Mesecar AD., Structural basis for catalysis of a tetrameric class IIa fructose 1,6-bisphosphate aldolase from Mycobacterium tuberculosis. J Mol Biol. 2009 Mar 6;386(4):1038-53. PMID: 19167403. [Featured Article/Cover]

47. Ratia K, Pegan S, Takayama J, Sleeman K, Coughlin M, Baliji S, Chaudhuri R, Fu W, Prabhakar BS, Johnson ME, Baker SC, Ghosh AK, Mesecar AD., A noncovalent class of papain-like protease/ deubiquitinase inhibitors blocks SARS virus replication. Proc Natl Acad Sci U S A. 2008 Oct 21;105(42):16119-24. PMID: 18852458.

48. Tipparaju SK, Joyasawal S, Forrester S, Mulhearn DC, Pegan S, Johnson ME, Mesecar AD, Kozikowski AP., Design and synthesis of 2-pyridones as novel inhibitors of the Bacillus anthracis enoyl-ACP reductase. Bioorg Med Chem Lett. 2008 Jun 15;18(12):3565-9. PMID: 18499454.

49. Pegan SD, Serrano H, Whitman CP, Mesecar AD., Structural and mechanistic analysis of trans-3-chloroacrylic acid dehalogenase activity. Acta Crystallogr D Biol Crystallogr. 2008 Dec;64(Pt 12):1277-82. PMID: 19018104. PMC2631126

50. Pegan S, Tan J, Huang A, Slesinger PA, Riek R, Choe S., NMR studies of interactions between C-terminal tail of Kir2.1 channel and PDZ1,2 domains of PSD95. Biochemistry. 2007 May 8; 46(18):5315-22. PMID: 17437338

51. Pegan S, Arrabit C, Slesinger PA, Choe S., Andersen's syndrome mutation effects on the structure and assembly of the cytoplasmic domains of Kir2.1. Biochemistry. 2006 Jul 18;45(28):8599-606. PMID: 16834334

52. Pegan S, Arrabit C, Zhou W, Kwiatkowski W, Collins A, Slesinger PA, Choe S., Cytoplasmic domain structures of Kir2.1 and Kir3.1 show sites for modulating gating and rectification. Nat Neurosci. 2005 Mar;8(3):279-87. PMID: 15723059

53. Pegan S, Kwiatkowski W, Choe S., Riek R., High-throughput backbone resonance assignment of small 13C,15N-labeled proteins by a triple-resonance experiment with four sequential connectivity pathways using chemical shift-dependent, apparent 1J(1H,13C): HNCACBcodedHAHB. J Magn Reson 165, 315-319, 2003. PMID: 14643715

Journal Articles: (Under peer-review or revision):


6

54. Height J, Bester SM, Guelta MA, Bae SY, Cheung J, Pegan SD., Insights into inhibition of human acetylcholinesterase by novel P-N phospho-fluoroamido- nerve agents (Unclassified Title), Accepted; slated for early 2021 issue of Journal of DoD Research and Engineering.

55. Wu Y, Pegan SD, Crich D, Hansen M, Starling E, Desrochers E, Booth C, Lou L, Chang KY, Xie ZR., Polyphenols as Alternative Treatments of COVID-19. In revision.

Bulletins or reports 56. Alsaidan O, Kim S, Goodwin O, Li Q, Bai A, Bielawska Alicja, Zheng G, Lebedyeva Iryna, Albers T, Norris

JS, Pegan SD, Cai H., (2018) A070: Targeting N-myristoyltransferase 1 inhibits prostate cancer progression, Cancer Research, 16 Supplement A070-A070

57. Rahman G, Pegan S, Cowen B., (2015) Diversity oriented synthesis of quinoline scaffolds employing acetal substrates in the Doebner-Miller reaction, Abstracts of Papers of the American Chemical Society, Volume 249

58. Park S, Bagriantsev S, Callan L, Pegan SD, Mesecar AD, Liebman S. (2008) P2-350: Yeast cell–based genetic and chemical screens for inhibitors of Aβ42 oligomerization, Alzheimer's and Dementia, Volume 4, Issue 4, Pages T475-T475

59. Joyasawal S, Tipparaju S, Pegan S, Mesecar AD, Kozikowski AP. (2008), MEDI 337-Synthesis and biological activity of A-33853 and its analogs. 236th National Meeting of the American-Chemical-Society. Volume 236

Peer-Reviewed Abstracts Presented at State/National/International Meetings and Conferences: Total of 42 (note: x indicates multiple abstracts presented at the same meeting/conference) • SERCAT 2021 Symposium, St. Jude’s Children Hospital, Memphis, March 19th, 2021 (2x) • CBD S&T 2019, Cincinnati OH, November 20, 2019 (2x) • Deubiquitylases: from mechanism to physiology, Edinburgh, Scotland, Jun 19, 2019 • 10th Southeast Enzyme Conference, Atlanta GA, Apr 13, 2019 (2x) • SERCAT 2019 Symposium, University of Alabama, Birmingham, Mar 15, 2019 • Negative Strand Virus 2018, Verona Italy, June 17, 2018 • Keystone Symposia Ubiquitin Signaling (A8), Lake Tahoe, Jan 30, 2018 (3x) • 8th Southeast Enzyme Conference, Atlanta GA, Apr 8, 2017 (4x) • Keystone – VHFV conference, Dec 4, 2016 • 6th European Congress of Virology, Hamburg, Germany, Oct 18, 2016 (3x) • Southern Translational Education and Research Conference (STAR), Sep 22, 2016 (4x) • Keystone Symposia- Positive-Strand RNA Viruses, Austin, TX May 2, 2016 • 2015 UGA Conference on Drug Discovery, Nov 17, 2015 • Southern Translational Education and Research Conference (STAR), Sep 24, 2015 • 1st International CCHFV Conference, Thessaloniki, Greece, Feb 13, 2015 (2x) • Viral Immunity, Keystone Symposia, Breckenridge, CO, Jan 11, 2015 • The 72nd Annual Pittsburgh Diffraction Conference, Athens, GA, Oct 26, 2014 • XIIIth Nidovirus Symposium, Salmanca, Spain, Jun 1, 2014 • Rocky Mountain Virology Conference, Pingree Park, CO Sep 27, 2013 (2x) • American Society for Microbiology General Meeting, Denver May 18, 2013 • University of Colorado Denver Structural Biology & Biochemistry, Denver, May 9, 2013 • Rocky Mountain Virology Conference, Sep29, 2012 • American Society of Crystallography, Boston MA, Jul 27, 2012 • UC Denver Structural Biology & Biochemistry Symposium, University of Colorado, Anschutz Medical

Campus, Denver CO, May 9, 2012 (2x) • 2nd Annual Molecular and Cellular Biophysics Symposium, University of Denver, Denver, CO, Apr 19, 2012 • The XIIth International Nidovirus Symposium, Traverse City, MI, Jun 4, 2011 • Ubiquitin Drug Discovery and Diagnostics, Philadelphia, PA, Jul 13, 2011 • Molecular and Cellular Biophysics Symposium, University of Denver, Denver, CO, Apr 8, 2011 • American Society of Pharmacognosy (ASP) meeting, Honolulu, HI, Jun 27, 2009


7

• XXVIII Midwest Enzyme Chemistry Conference, Chicago, IL, Oct 4, 2008 • Keystone Symposia; Linking Cardiac Arrhythmia to Gene Defects, Lake Tahoe, CA, Feb 1, 2006

PATENTS AND PATENTS PENDING 1. Compositions and methods for treatment for SARS-CoV-2 through papain protease inhibition, Pegan SD,

Durie I; Freitas B, Tripp R, Cummings B, Crich D, Ahiadorme D, Subedi Y, Onobun E, Hill J, Upadhyaya K, Pirrone M, Bagul R, University of Georgia, provisional patent filed 63/086,137, October 1, 2020

2. Compositions and Methods for Treatment of SARS-CoV-2, Pegan SD, Tripp RA, Freitas B, University of Georgia, provisional patent filed 62/992,895, March 20, 2020, PCT filed March 22, 2021 (Licensed)

3. Crimean-Congo Hemorrhagic Fever Virus Replicon Particles and use thereof, Bergeron E, Florine FEM, Nichol S, Welch SR, Spengler J, Spiropoulou CF, Pegan SD, University of Georgia & Centers for Disease Control and Prevention, provisional patent filed 62/780,098 December 14, 2018, PCT filed December 13, 2019.

4. Engineered Organophosphorus Acid Anhydrolases and Methods of Use Thereof, Pegan SD, Harvey S., University of Georgia & U.S. Army Edgewood Chemical Biological Center, US 10,260,054, April 16, 2019

5. Attenuated Live Vaccine for Crimean-Congo Hemorrhagic Fever virus and Erve Virus, Pegan SD, Nichol S, Bergeron E., Deaton M., University of Denver & Centers for Disease Control and Prevention, US 9,795,665, October 24, 2017 [Awarded an Outstanding Achievement and Invention Award]

6. Crimean-Congo Hemorrhagic Fever Virus Vaccine, Pegan SD, Nichol S, Bergeron E., Deaton M., University of Denver & Centers for Disease Control and Prevention, US 9,474,796, October 25, 2016, WO2014028511A1, EP2884998A4

7. Antibiotic and anti-parasitic agents that modulate Class II fructose 1,6 bisphosphate aldolase, Pegan SD, Capodagli GC, Cowan B, Ahrent K, University of Denver, US 9,394,254 B2, July 19, 2016, WO2014182954A1, EP2994142A4

8. KIR Channel Modulators, Pegan S, Choe S, Slesinger P, Prafulla A., Salk Institute for Biological Studies, US 8,097,422, January 17, 2012

INVITED TALKS AND SEMINARS AND SELECTED MEDIA AND PRESS Invited Science Talks and Seminars 1. “Keeping the DoD up at Night: Countering Nerve Agents and Viral Threats,” University of California Santa

Cruz, talk to be given on May 5th, 2021. 2. “Things that Keep the DoD up at Night: Countering Nerve Agents and Viral Threats”, Division of

Biomedical Sciences, UC Riverside, Dec 7, 2020 3. “Using X-ray crystallography for gaining insight into stereospecific obstacles related to nerve agent

therapeutics,” Structure of Cholinesterases a session of The 2nd International Online Conference on Crystals Nov 19th, 2020

4. “CCHFV host immunity suppression and creation, a story of a viral OTU protease and viral replicon particles,” Tofo 4th Tofo Advanced Study Week on (Re-)Emerging Viruses, Mozambique, September 4, 2019

5. “Using X-ray crystallography for gaining insight into stereospecific obstacles related nerve agent therapeutics,” CBRNE Detection & Protection Workshop, Warsaw, Poland, April 18, 2019

6. “Using X-ray crystallography for gaining insight into stereospecific obstacles related nerve agent therapeutics,” Epimilitaris, Castle Ryn, April 16, 2019

7. “Closing technology gaps against DoD threats: From nerve agent therapeutics to leveraging viral deubiquitinases in virulence and their species-specificity for antiviral therapeutic strategies,” Defense Threat Reduction Agency, March 19, 2019

8. “Developing countermeasures against DOD threats from decoding the role of viral deubiquitinases in virulence and species-specificity to nerve agent therapeutics,” Defense Threat Reduction Agency, December 18, 2018


8

9. “Decoding the role of viral deubiqutinases in virulence and species specificity,” Center for Vaccine and Immunology, University of Georgia, Oct 3rd, 2018

10. “Sharing the different facets of crystallography pertinent to therapeutic development against DOD threats,” Recent Advancements in XRD & Cryo-EM for Unraveling Biological Structure & Function: A Workshop to Explore Applications in Chemical & Biological Defense, DTRA, Lorton, VA Aug 29th, 2018

11. “Impact of ISG15 species-species variation on ISG15 structure and viral-host interactions,” Cells vs. Pathogens: Intrinsic Defenses and Counter Defenses, Keystone Symposia, Monterey, CA Mar 24, 2018.

12. “Decoding the role of viral deubiqutinases in virulence and species specificity,” University of California Santa Cruz, Mar 23, 2018

13. “Preference of CCHFV and Other Nairovirus vOTUs for Interferon-Stimulated Gene Product 15 Originating from Certain Species,” 2nd International Conference on Crimean-Congo Hemorrhagic Fever, Thessaloniki, Greece, Sep 11, 2017

14. “Using X-ray crystallography for gaining insight into stereospecific obstacles related to nerve agent therapeutics,” Defense Synchrotron Consortium at Brookhaven National Laboratory, DTRA Jun 13, 2017.

15. “Structural insights of stereo-specific inhibition of hAChE by VX and subsequent Reactivation by HI-6,” U.S. Medical Research Institute of Chemical Defense, Mar, 9, 2017

16. “Species-dependent ISG15 variation impacts viral protease function” 68th Southeastern Regional Meeting of the American Chemical Society, Oct 26, 2016

17. “Biodiversity impact of host interferon-stimulated-gene-product 15 on the function of viral deISGylases” SERCAT 2016 Symposium, Emory University, Mar 19, 2016

18. “Engineering the OPAA Enzyme for Increased Catalytic Efficiency and Broadened Stereospecificity on Russian VX,” DTRA Enzyme Colloquium, Fall Church, VA Mar 31, 2016

19. “A Journey into the world of Nairovirus Ovarian Tumor Domain Proteases and implications for therapeutic discovery.” Mercer University College of Pharmacy, Oct 19, 2015

20. “The unique substrate specificity of the viral ovarian tumor domain protease from the Crimean-Congo Hemorrhagic Fever Virus” 1st International CCHFV Conference, Thessaloniki, Greece, Feb 13, 2015

21. “Seeking Validation … A Journey in the Discovery of Lead Inhibitors Against the Nairovirus Ovarian Tumor Domain Protease” Stanford Research Institute, Jan17, 2014

22. “Seeking Validation…. A Journey in the Discovery of Lead Inhibitors Against the Nairovirus Ovarian Tumor Domain Protease” Purdue University, Oct 2, 2013

23. “Seeking Validation … A journey in lead discovery for putative TB and nairovirus pharmaceutical targets,” The Buck Institute for Research on Aging, Jul 26, 2013

24. “Nairovirus OTU de-ubiquitinases, a new approach for selective antiviral therapeutics with a way forward for broad-base applications,” Rocky Mountain Virology Conference, Sep 29, 2012

25. “Nairovirus OTU de-ubiquitinases, a new approach for selective antiviral therapeutics with a way forward for broad-base applications,” Walter Reed Army Institute for Research, Aug 14, 2012

26. “Potential of developing selective and broad-based antivirals through inhibition of OTU deubiquitinases” Department of Pharmacology, University of Colorado School of Medicine, Jan 19, 2012

27. “Potential of developing selective and broad-based antivirals through inhibition of OTU deubiquitinases,” Millennium (subsidiary of Takeda Pharmaceutical Company), Nov 3, 2011

28. “New Approaches for Antiviral Treatments,” Viral Special Pathogen Branch, U.S. Centers for Disease Control and Prevention, Jul 21, 2011

29. “Targeting deubiquitinating enzymes for up-regulation of the innate immune response,” Department of Biochemistry and Molecular Genetics, University of Colorado School of Medicine, Mar 2, 2011

30. “New Approaches for Antiviral and Antibiotic Treatments,” Department of Biology, University of Denver, Jan 10, 2011

31. “Drug Discovery with viral ovarian tumor proteases,” University of Northern Colorado, Nov 10, 2011 32. “Viral ovarian tumor proteases,” University of Denver NSM Emeritus Faculty Club, Sep 10, 2010


9

33. “Structural Characterization of tetrameric Mycobacterium tuberculosis fructose 1,6-bisphosphate aldolase - substrate binding and catalysis mechanism of a class IIa bacterial aldolase,” XXVIII Midwest Enzyme Chemistry Conference, Oct 4, 2008

34. “Academic Drug Discovery Using Small Scale Robotics,” Chicago Biomedical Consortium workshop, Jul 8, 2008

35. “High Throughput Screening (HTS) Techniques for Academia Target Based Drug Discovery,” Lawrence Livermore National Laboratory, Biosciences & Biotechnology Division, Jun 29, 2007

36. “Molecular Gating Dynamics of the Cytoplasmic Domains of Inwardly Rectifying Potassium (Kir) Channels,” Division of Biology, University of California, San Diego, Nov 25, 2006

37. “Molecular Gating Dynamics of the Cytoplasmic Domains of Inwardly Rectifying Potassium (Kir) Channels,” Keystone Symposia Short Talk Speaker; Linking Cardiac Arrhythmia to Gene Defects, Feb 1, 2006

38. “Structure of Potassium Inwardly Rectifying Channel 2.1,” Molecular Biophysics Training Program, University of California, San Diego, Oct 10, 2005

Select Media Coverage

• Highlighted in UGA Today in an article entitled, “Promising path found for COVID-19 therapeutics” June 2020

• Finch Podcast COVID-19 Series, Episode 5, May 2020 • WUGA 2020 Broadcast, Topic COVID-19 vaccine development and regulatory approval • Highlighted in UGA Today in an article entitled, “College of Pharmacy, CDC develop vaccine for virus”

April 2019 • Highlighted in UGA Today in an article entitled, “New lab works to develop treatment of leading diseases,”

November 2017 • Highlighted in the UGA RX Magazine in an article entitled, “Pegan Research Focuses on Orphan, or Neglected,

Diseases”, Spring 2016 Issues • WUGA Classic City Science 2016 Broadcast, Topic Nerve Gas Therapy, September 2016 • WUGA Classic City Science 2016 Broadcast, Combatting Hemorrhagic Fever, September 2016 • U.S. Army’s The 71B Quarterly Newsletter, 4th QTR 2015, Delivering Science and Technology for RDECOM:

71B Reservist Taking Technology to the Warfighter • U.S. Army’s The 71B Quarterly Newsletter, 4th QTR 2015, 71Bs DEFINING EXCELLENCE • U.S. Army Article, August 6, 2016, Scott Pegan was highlighted by the US Army for his scientific advising

during a Joint US and Australian exercise. (www.army.mil/article/153451/Army_technology_advisors_connect_with_Soldiers_in_Talisman_Sabre_15/)

• University of Georgia's Focus on Faculty, January 2015, Scott Pegan was selected by the University of Georgia Provost's Office to be featured in this article that showcases his research, teaching, and service. (https://news.uga.edu/pegan-scott/)

• Structure of the Month, March 2009, Scott Pegan’s Tuberculosis 1,6 bisphosphate aldolase structure was showcased by Rigaku.

• Elastic Gateway in Ion Channel Discovered, July 29, 2005 Stanford Synchrotron Radiation Laboratory Scientific Highlight, http://www-ssrl.slac.stanford.edu/research/kir_summary.html

RESEARCH GRANTS AWARDED Current and Pending Research Grant Funding

1. Army-CBC Role – PI (Pegan) Pending - $ 710,819 08/15/21 – 08/14/2024 Title: Identifying Host Pathways Important to Protective Immunity Against CCHFV The goal of this study is to obtain structural biological data to assist in anti-nerve agent therapeutic development.


10

2. DTRA HDTRA12110005 Role – PI (Pegan) $ 799,446 11/09/20 – 11/08/2023 Title: Identifying Host Pathways Important to Protective Immunity Against CCHFV The goal of this study is to determine monoclonal antibodies correlates of protection for CCHFV using a new

CCHFV viral replicon particle vaccine. 3. NIH 1R01AI151006-01A Role – PI (Pegan) $1,733,197 09/16/20 – 08/31/2025 Title: Origin of the innate immunity suppression caused by nairovirus' protease activity

The goal of this study is to determine delineate the impact of specific viral ovarian tumor domain protease substrate specificity on down regulation of the innate immune system and subsequent disease severity.

4. Industry - AWD00012621 Role – PI (Pegan) $197,399 10/1/2020 – 9/30/2021 Title: Creation and Testing of Peptide-Based Coronavirus PLpro Inhibitors The goal of this study is to develop peptidomimetic based inhibitors of the papain-like protease from SARS-CoV-2.

5. Industry – AWD00012787 Role – PI (Pegan) $259,805 02/1/2020 – 1/31/2021 Title: COVID-19; In vivo efficacy and toxicology of SARS-PLpro Leads The goal of this study is to perform in vivo efficacy and toxicity testing in order to further development of small molecule-based inhibitors of the papain-like protease from SARS-CoV-2.

6. NIH S10 OD028613-01A1 Role – Major User (Garg) $547,000 02/1/21-01/31/22 Title: Flow cytometer Cell Sorter for Biosafety Level-3 Facility The major goal of this funding is to obtain a new flow cytometer for the UGA BSL-3 laboratory space.

Completed

1. “A path to structurally guided enhancement of acetylcholinesterase reactivators and resurrecting agents” Scott Pegan (PI), DoD U.S. Army W911SR-17-C-0024, $551,372, FEB2017-SEP2020

2. “Acquisition of a High Precision Micro Diffractometer to Support NIH funded Research at SER-CAT” Scott Pegan (Key Person; PI-John Rose), NIH 1S10OD027000-01, $599,999, FEB2020 – AUG2020

3. “Origin of the innate immunity suppression caused by nairovirus' protease activity” Scott Pegan (PI), NIH 1R01AI109008-01, $1,542,295, NOV2013-OCT2019

4. “Role of the viral ovarian domain protease in PRRSV pathogenesis,” Scott Pegan (Co-I; PI Kay Faaberg), National Pork Board, $201,367 (Co-I $108,813), NOV2015 – OCT2017

5. “Acquisition of an X-ray Generator/Detector System to Support NIH Research,” Scott Pegan (Key Person; PI-John Rose), NIH 1S10OD021762-01, $413,002, AUG2016 – JUL2017

6. “Porcine Epidemic Diarrhea Virus (PEDV) and Porcine Delta Coronavirus (PDCoV) Protease Function and Modification to Improve Swine Innate Immunity”. Scott Pegan (PI), USDA 58-5030-5034, $260,442, DEC2014 – NOV2016

7. “National Institutes of Health NIAID Research Supplement to Promote Diversity,” Scott Pegan (PI), NIH R01AI109008-03S1, $147,825

8. “Molecular probes for a vOTU from CCHFV using a fluorogenic peptide,” Scott Pegan (PI), NIH R03 MH097507-01A1, $74,600, SEP2012 – AUG2015

9. "Macromolecular X-ray Data Collection Instrumentation," Mair Churchill (PI), Scott Pegan (Key Person), NIH, 1S10OD012033-01A1, $591,505, APR2014-APR2015

10. “UGA Contracted Consulting for structural biology guided enhancement of OPAA’s stereospecificity for nerve agents,” Edgewood Chemical Biological Center, U.S. Army, $13,000 JAN2014- DEC2015

11. “Crimean Congo hemorrhagic fever therapeutics through inhibition of vOTU,” Scott Pegan (PI), Colorado Center for Drug Discovery, $10,000, APR2013-MAY2014.

12. “Assessment of deubiquitinating and deISGylating activity; specificity motifs among viral Ovarian Tumor Domain Proteases,” Scott Pegan (PI), NIH, R03 AI092249-01, $144,052, SEP2011-AUG2014

13. “Establishing a Molecular Model for Improved Diagnosis of ADSL Severity,” Scott Pegan (Co-PI) with Kingshuk Ghosh (Co-PI) and David Patterson (Co-PI), University of Denver, Interdisciplinary Research Fund, $60,000, JAN2011-JAN2013


11

14. “Lead Optimization of Small Molecules for Novel TB Therapeutics through Inhibition of MtFBA,” Scott Pegan (PI), Colorado Center for Drug Discovery, $20,000, MAY2011-FEB2012

15. “Structural and Computationally Guided Inhibitors for a Class II Aldolase of TB,” Scott Pegan (Co-PI) with Andrei Kutateladze (Co-PI), University of Denver, Professional Research Opportunities Fund, $30,000, JUL2010-JAN2012

16. Natural Sciences and Mathematics Division equipment funding 2010 & 2011. Scott Pegan was a (Co-PI) on two successfully funded interdisciplinary NSM equipment proposals that resulted in the procurement of static light scattering device, isothermal calorimetry, and multi-wavelength plate reader devices. $170,000.

17. “In the Foot-steps of the Nobel Laureates: The Biochemistry of Green Fluorescent Protein,” Michelle Knowles, Scott Pegan, and Martin Margittai (Co-PI), University of Denver, Office for Teaching and Learning, $20,000, JAN2009-DEC2010

18. “Institute for Advanced Pharmaceutical Sciences, Molecular Targets and Drug Screens to Combat Bioterrorism,” Scott Pegan (Co-investigator), Department of Defense, W81XWH0710445 USAMRAA, $888,000 (Co-I, ~$128,648), OCT2007-SEP2008

SCIENTIFIC REVIEWER AND REVIEWER PANELS Journals Routinely Served as a Scientific Reviewer

• PLoS One

• Tuberculosis Research and Treatment • PLoS Pathogens • Journal of Virology • Antiviral Research

• Biochemie • Biochemistry • Journal of the American Chemical Society

• Scientific Reports • Acta Cryst Sections D,F • Virology Methods • Antimicrobial Agents and Chemotherapy (ACC) • Journal of the American Chemical Society • Nature Communications

Grant Review Panels

• NIH NIAID • DTRA – Basic Science Program Review • USDA ARS • Research Foundation CUNY • British Medical Research Council • Congressionally Direct Research Programs (Member-Tick-borne; Chair-COVID-19) • Combat Casualty Care Research Program • Broad Agency Announcement for Extramural Medical Research

PROFESSIONAL MEMBERSHIPS 2010 – Present Member, American Society of Microbiology (ASM) 2009 – Present Member, American Chemical Society (ACS) 2000 – Present Member, American Association for the Advancement of Science (AAAS)

TEACHING ACTIVITIES Sole instructor and Course Coordinator are indicated by (*) and (u) respectively

Undergraduate

CHEM 1010* General Chemistry, first year required course for science and engineering fields at DU (2009-2013). This course was initially a traditional lecture class that was converted to a hybrid format with active student learning for 2012-2013.

CHEM 1240* General Chemistry Laboratory, first year laboratory for science and engineering fields at DU (2010-2011). This course was completely redesigned for 2011 (first time in >10 years) in order to be more relevant to evolving science and engineering degree programs


12

CHEM 3812* Biochemistry - Membranes & Metabolism, upper division course at DU (2010-2014). This course initial was a pure didactic course and was subsequently infused with active student learning components for 2011-2014.

CHEM 3391/3995* Research in Chemistry, upper division course at DU (2010-2014). This course was to provide undergraduates with not only research experiences, but experience in scientific presentation and writing.

PMCY 2020* Pills, Potions, and Modern Medicines, lower division course at UGA (2020-Pres.). Responsible for course creation and teaching 10% of this course, which was designed to introduce lower division students to pharmacy topics from bench to bedside.

PMCY 4300 Medicinal Chemistry, upper division course at UGA (2015-Pres.). Responsible for developing and teaching 50% of this course, which is a requirement for the College of Pharmacy’s sole undergraduate degree program.

XXXX 4960-70* Undergraduate Research course in BIOL, BCMB, and PMCY, at UGA (2014-Pres.). This course series provides undergraduates with scientific experiences in research, presentation, and writing.

Graduate / Professional

CHEM 3320* Structure and Energetics II, graduate level course at DU (2013-2014). This course was redesigned to offer the fundamentals and practical application of computational / cheminformatics techniques

PHRM 8050u Pharmaceutical and Biomedical Analysis, graduate level course at UGA (2015). Redesigned and taught 35% of this core doctoral program offering.

PHRM 8010u Structural Biology and Medicinal Chemistry, graduate level course at UGA (2016-Pres.). Created the course on a layout comprising a mixture of didactic and experiential driven projects. Teach 35% of this core doctoral program offering.

PMCY 6300 Medicinal Chemistry, graduate course version of PMCY 4300 at UGA (2016-Pres.). Responsible for developing and teaching 50% of this course, which is central the College of Pharmacy’s Master’s degree program.

PMCY 4410/6410*u Robotic Technology in Drug Discovery and Toxicology, a undergraduate/professional/graduate course at UGA (2018-Pres.). Responsible for developing and teaching this 100% online course to service the College of Pharmacy’s Bachelors, Master and PharmD degree programs.

CHEM 4900u Departmental Seminar at DU (2011-2012). CHEM 4995/5994*u Independent Research, doctoral level course for research at DU (2010-2014) BIOP 4992-5/5995*u Independent Research, doctoral level course for research at DU (2010-2014) PHRM 8080 Grantsmanship, a doctoral level course at UGA (2015-Pres.) PHRM 7000*u Master Research, a graduate level course at UGA (2017-Pres.) PHRM 9000*u Doctoral Research, a doctoral level course at UGA (2015-Pres.)

Teaching Development

1. VIP Observer of the AP Reading (June 2018) • Invited as a VIP observer to the College Boards Advance Placement Reading Event in Salt Lake City • Current status of AP education in the high school and relationship with college level curriculum • Consulted on ways to improve AP’s relationship and offers to meet current degree needs

2. F-2-F meeting - hybrid course workshop (Summer 2012) • Summer professional development course on development, implementation, and assessment of hybrid and

online courses

Degree Programs Developed


13

1. BS Pharmaceutical Sciences – Pharmacy Doctorate Dual Degree program, University of Georgia • Led the 2021 creation and shared governance passage of a dual degree BS Pharmaceutical Sciences –

Pharmacy Doctorate. Program is currently undergoing university level administrative review with an expected launch date of Fall 2021.

2. Master’s of Pharmacy (BS/MS, thesis & non-thesis), University of Georgia • Led the 2020 revision of the College of Pharmacy’s Master’s degree program. This revision brought the

program in line with its contemporaries in terms of program length, but also reinvigorated it terms of content to reflect the advancements in biopharma and biotechnology industry. Also, spearheaded the adoption of a new non-thesis option that is paving the way for an online degree offering track.

3. Concentration in Biochemistry; Bachelor of Science in Chemistry (BSCh), University of Denver • Developed, pushed through approval and implemented a new degree program that allowed for individuals

performing biochemistry related research and taking a biochemistry centric degree program to receive an ACS approved degree with a concentration related to their true field of study

Teaching Related Grants 1. University of Georgia OOL Role - Co-PI (Pegan) $50,000 12/1/17 – 8/30/2019 Title: Drug Discovery Active Learning While Gaming (DDAWG) The goal of this funding is to develop an innovative online graduate course series surrounding the drug discovery process and how robotics and chemical informatics techniques are utilized within that process.

ADVISING AND MENTORING ACTIVITY Graduate Students: (Dissertation/thesis completed (8), uauthorships (55)) Ian Durie (Ph.D.)uu Current 2019 – Projected 2023

• Awarded 2020 Junior PBS Student of the Year, UGA College of Pharmacy • Selected for UGA internship with Boehringer Ingelheim

Brady O’Boyle (Ph.D.) Transferred upon move to UCR 2020 – 2021. • Best Poster Co-Awardee SERCAT Symposium, St. Jude’s Hospital, Mar 19, 2021

Justin Shepard (Ph.D.). Transferred upon move to UCR 2020 – 2021. • Best Poster Co-Awardee SERCAT Symposium, St. Jude’s Hospital, Mar 19, 2021

Brendan Freitas (Ph.D.)uuuuuuuu Graduated 2017 – 2021 Post-Doc CU Anschutz

• Finalist for the LaRocca Best Senior Doctoral Dissertation Award (Award Pending), UGA College of Pharmacy

• Invited speaker at Deubiquitylases: from mechanism to physiology, Edinburgh, UK June 19, 2019

Jack McGuire (M.S.)uuu Graduated 2018 – 2020 Medical School Applicant Caroline Langley (M.S.)uuu Graduated 2017 – 2019 Doctoral Program UW Stephanie Bester (Ph.D.)uuuuuuu Graduated 2015 – 2019 Post-Doc CU Anschutz

• First authored a Science paper within 1 year of receiving graduating • Finalist for the LaRocca Best Senior Doctoral Dissertation Award • Awarded the 2019 Southeast Regional Collaborative Access Team Young Investigator Award • Invited speaker at the 2019 SERCAT Symposium, University of Alabama, Birmingham, Mar 15, 2019 • Awarded 2018 Outstanding Poster, PBS Research Day, UGA College of Pharmacy • Invited speaker at the 2017 Chemical and Biological Defense Science and Technology Conference, Long

Beach, November 28, 2017

John Dzimianski (Ph.D.)uuuuuuuuuuu Graduated 2015 – 2019 Post-Doc UC Santa Cruz

• Finalist for the LaRocca Best Senior Doctoral Dissertation Award • Awarded 2017 Junior PBS Student of the Year, UGA College of Pharmacy


14

Courtney Daczkowski (Ph.D.)uuuuuuuu Graduated 2014 –2018 Post-Doc Purdue

• Finalist for the LaRocca Best Senior Doctoral Dissertation Award • Awarded the 2013 Stewart Endowment Award, “Best Senior Doctoral Student,” UGA College of Pharmacy • Invited speaker Nido2017, Kansas City, June 7, 2017

Michelle Deaton (Ph.D.)uuuuuu Graduated 2010-2015 Scientist at GE

• Runner up, “2014 Best Research Student,” DU Division of Natural Sciences and Mathematics

Glenn Capodagli (Ph.D.)uuuuuuuu Graduated 2010-2014 Post-Doc Rutgers • Awarded Outstanding Student Poster at the ASM General Meeting, Denver May 18, 2013 • Awarded the 2013 John M. Stewart Poster Award, University of Colorado Medical School • First student to complete University of Denver’s Molecular Biophysics Doctoral Program

Graduate Student Committee Member: Tyler Brown PI–Dr. Y. George Zheng 2018 – 2021 Emma Troth PI –Dr. Dennis Kyle 2018 – 2021 Derrick Afful PI –Dr. Cory Momany 2015 – 2019 Melody Fulton PI –Dr. Y. George Zheng 2017 – 2019 Laura Wilt PI –Dr. Arthur Roberts 2014 – 2018 Kun Qian PI –Dr. Y. George Zheng 2014 – 2017 Benton Cartledge PI –Dr. Brian Majestic 2010 – 2014 Philip Cheney PI –Dr. Michelle Knowles 2009 – 2014 Domicinda Hill PI –Dr. Bob Dores 2012 – 2012 Ayisha Siddiqua PI –Dr. Martin Margittai 2009 – 2012

Undergraduate Students: (*thesis completed (8), uauthorship (17)) Enrolled, Graduated, or Progressed Early to Graduate Education Mary Johnson 2020 – 2021 Proj. Graduate UGA PMCY 2023 Carson Moriarty 2020 – 2021 Proj. Graduate UGA PMCY 2023 Suzanne Enos 2019 – 2021 Proj. Graduate UGA PMCY 2022 Holden Milleru 2019 – 2021 Proj. Graduate UGA PMCY 2022 Jaron Longou 2019 – 2021 Medical School Applicant Sam Swift 2020 – 2021 Ph.D. Program Univ. Colorado Boulder Isabelle Williamsuu 2017 – 2020 VCU School of Medicine for an MD Ashton Clary 2018 – 2019 UIC School of Pharmacy for PharmD Savannah Maceu 2017 – 2019 UGA School of Pharmacy for PharmD Kailee Baker 2018 – 2019 Ph.D. Program Univ. Kentucky Brianna Beldonu 2015 – 2018 UGA School of Pharmacy for PharmD Chiamaka Mediatrix 2014 – 2016 Vanderbilt Medical School Olivia Nechvatal 2014 – 2016 UGA School of Pharmacy for PharmD Emily Garland 2014 – 2015 UGA School of Pharmacy for PharmD Melanie Parhamu 2014 – 2015 M.S. Program Mercer Univ. Wafik Sedhom*u 2011 – 2015 Univ. Colorado Medical School Elyssa Goldstein* 2011 – 2015 Rocky Vista College of Osteopathic Medicine Stephen Alex Leeu 2013 – 2015 Rocky Vista College of Osteopathic Medicine Megan Gillette 2012 – 2014 Midwestern University School of Medicine Lauren Calkins*u 2010 – 2014 Pharm.D. Program Univ. Wisconsin Ryan Lumpkin*u 2011 – 2014 Ph.D. Program Univ. California San Diego Erica Baker*uuuu 2009 – 2013 Ph.D. Program Purdue University Mike Flanagan 2011 – 2012 Entrepreneur, IT & Security Company Marissa McKercher*u 2009 – 2011 Ph.D. Program Univ. Colorado Boulder Sean Connor*u 2009 – 2011 Graduated LSU Medical School/NM Residency Grant Ruehle* 2009 – 2011 New Belgium Brewing Company


15

Non-University Summer Internship: (u authorships (2)) Becca Lidvall (High School) Graduated Univ. Colorado Boulder Emily Masters (Northwestern UG)u Engineer DOW Chemical Sarah Brown (High School) UGA Young Dawgs Spring 2016 Alexis Shirley (High School) UGA Young Dawgs Fall 2016 Catherine Argabright (High School) UGA Young Dawgs Summer 2016 Aryan Gupta (High School) UGA Young Dawgs Summer 2017 Johnathan Farhat (High School)u UGA Young Dawgs Summer 2017 Abdullah Chandasir (High School) UGA Young Dawgs Summer 2018 Vishnavi Batchu (High School) UGA Young Dawgs Summer 2019 Jenna Meadow (High School) UGA Young Dawgs Fall 2019

Postdoctoral Fellow: (u authorships (5)) Dr. Octavia Goodwinuuuuu 2015– 2017 Scientist, Protein Purification, Bio-Rad Dr. Jaeyoung Song 2014– 2015 Senior Scientist, Adjunct Prof. Daegu Gyeongbuk Medical Innovation Foundation, South Korea

ACADEMIC PROFESSIONAL EXPERIENCE University of Georgia (2014-2021) 2020 – 2021 Interim Associated Department Head, Pharmaceutical and Biomedical Sciences. 2019 – 2020 Chair, BS and BS/MS Committee (Preceding title)

• Coordinates PBS Academic Programs (Graduate & Undergraduate) to facilitate continuity and to ensure congruent delivery, evaluation and assessment of PBS Teaching responsibilities in the Pharm.D., B.S. and Graduate Programs.

o Supervised 2020 Academic Program Review for BS, MS, and Ph.D. program components in order to maintain SACSCOC accreditation.

o Designed and implemented a data driven student management regimen that tracked student flows and revealed inefficiencies that impacted student experiences, graduation rates, and student intake.

o Developed faculty led review and awarding procedures for student scholarship and awards. • Works with PBS Committee Chairs and day-day supervises Graduate Coordinator and the Director of

the B.S. Program to review the content and delivery of current curriculum and develop new curriculum and to ensure progression with regards to committee charges.

o Passed three revamped MS level programs; updated BS curriculum to reflect developments within the associated fields in the last five years

• Oversees departmental efforts with regards to marketing and recruitment of the PBS B.S. and Graduate Programs.

o Developed and deployed a new comprehensive college level marketing strategy • Made recommendations to the Department Head with regards to teaching needs in PBS. • Serves as an alternate to the Department Head for approval of purchasing, time and travel requests grant

and contract submissions. • Assist in faculty annual reviews as well as departmental promotion and tenure processes. • Represented Department Head in his absence at all college activities (e.g., committees) and in related

roles. Department has 25 tenure-track faculty, 1 Clinical faculty, 2 Research faculty, and 1 lecturer. 2020 – 2020 Project Lead for the College of Pharmacy’s COVID-19 preparations and implementation

• Charged by the Dean with developing a crash program of preparation to prepare College of Pharmacy’s business continuity plan for the COVID-19 response

• Led a cross cutting group of faculty and administrators that developed a multi-faceted business continuity plan within 5 days. This plan created leadership and planning structures as well as tools necessary to implement a response to COVID-19 across the College’s tripartite mission

• Led the implementation effort of the College’s business continuity plan.


16

o This resulted in immediate remote instruction continuity of the PharmD program’s P3 and P4 years that safe guarded accreditation body required experiential learning and on-time graduations. Rolled out within a week a high-quality remote delivery of instruction for PharmD program’s P1 and P2 years. Ensured on time resumption of BS, MS, and PhD programs.

o Supervised policy generation and implementation to safeguard research progress and research infrastructure equipment for the entire College of Pharmacy’s research and scholarship portfolio. This resulted in the effective and responsible drawing down of a $8 M per year research program as well as stage for its restart.

2020 – 2020 Project Lead for the College of Pharmacy’s COVID-19 preparations and implementation • Charged by the Dean with developing a crash program of preparation to prepare College of Pharmacy’s

business continuity plan for the COVID-19 response • Led a cross cutting group of faculty and administrators that developed a multi-faceted business

continuity plan within 5 days. This plan created leadership and planning structures as well as tools necessary to implement a response to COVID-19 across the College’s tripartite mission

• Led the implementation effort of the College’s business continuity plan. o This resulted in immediate remote instruction continuity of the PharmD program’s P3 and P4 years

that safe guarded accreditation body required experiential learning and on-time graduations. Rolled out within a week a high-quality remote delivery of instruction for PharmD program’s P1 and P2 years. Ensured on time resumption of BS, MS, and PhD programs.

o Supervised policy generation and implementation to safeguard research progress and research infrastructure equipment for the entire College of Pharmacy’s research and scholarship portfolio. This resulted in the effective and responsible drawing down of a ~$8 M per year research program as well as stage for its restart.

2019 – 2021 Director of the University of Georgia’s Center for Drug Discovery 2018 – 2019 Interim Director of the University of Georgia’s Center for Drug Discovery

• Led a transition of the Center from a lecture series (virtual center) to a center offering services. • Developed a business plan through cross-university collaboration with OVPR, College of Veterinary

Medicine, Complex Carbohydrate Research Center, Center for Molecular Medicine, College of Pharmacy, as well as Franklin College (Cell Biology, Chemistry)

• Led a joint Center for Drug Discovery / Center for Toxicology initiative that infused >$150 K in equipment for use in drug discovery.

• Boosted drug discovery applications credited to the center to over $18 M with approximately $3 M in those selected for awards in 2020.

• Spearheaded a new e-learning initiative embodied as the Drug Discovery Active Learning While Gaming (DDAWG) Online Course Series. This series is designed to leverage the center’s recent acquisition of liquid handling robotic equipment for use in high-throughput screening and the exploding interest in the drug discovery process. Not only did I spearhead the concept of the series, but I also spearheaded the effort to acquire funding for the initiative. Specifically submitting a successful proposal to UGA’s Office of Online Learning. Responding to their first solicitation to fund on-line learning proposals, our proposal was selected from a highly competitive field with 1-2 others for a $50,000 award.

• Successfully recruited 5 drug discovery centric faculty members including an eminent scholar. This brought in multimillion dollars in research dollars through new and transferred awards.

• Increased Federal and State lawmaker awareness and funding of UGA of research endeavors in collaboration with government affairs through congressional staff engagement activities.

2018 – 2019 Interim Director of the University of Georgia’s Office of Experiential Learning • Exercised supervisory and budgetary authority over Georgia’s Office of Experiential Learning (EL).

This office is task with implementation of the university’s 2016 university wide requirement that all undergraduates will have carried out at least one EL opportunity. This is a first in the nation program for a large public university (~28,000 undergraduates). This office ensures that EL is not an


17

academically adjacent program, but one that is built into the educational fabric of Georgia through a faculty driven process with input from all stakeholders. This program is not only designed to differentiate Georgia’s graduates to aid them in obtaining their first job but provide them the tools to accelerate them through this first phase of employment.

• Oversaw a growing office of four full-time positions and one student employee. The director and teamwork with faculty from 17 college and schools of Georgia across the full spectrum of disciplines to set guidance. Also, the office works directly with ~130 EL devoted personnel across campus in order to provide over 1,600 individual EL opportunities to a diverse student population. Additionally, the office coordinates with numerous university level offices such as those dealing with service learning and student affairs as well as university legal for the create of MOUs associated with the office.

• Continuously developed for the enhancement of a ~$160,000 endowed scholarship program. This program is designed to offer scholarships in the range of $1,000-$3,000 to undergraduates based on need, originality of EL activity to be supported, and previous student performance. Also, I perform similar tasks for a $50,000 a year EL innovation grant program designed to promote, and support faculty launched EL approved endeavors.

• Responsible for office development and communication activities of this $500,000 annually budgeted office. These include furthering the development and impending launch of a first of its kind EL transcript.

• Responsible for developing and dealing with assessment of the programs activities to include establishment of tracking mechanisms for EL compliance by degree seekers.

NATIONAL COMMITEES 2019 – 2020 U.S. Southeast Representative, National Council of Faculty Senates (“NCFS”) 2019 – 2020 Interim Executive Committee Member, Mission and Vision statement.

• An organization to assist in spreading best practices of faculty shared governance • Seeks to build mutually beneficial communication mechanisms between faculty, University/College

officials, and University Regents/Trustees

STATE OF GEORGIA COMMITTEES 2019 – 2021 University System Healthcare Total Rewards Subcommittee (Invited) 2019 – 2019 Past Chair, University System of Georgia Faculty Council (Elected) 2018 – 2019 Chair, University System of Georgia Faculty Council (Elected) 2017 – 2018 Chair Elect, University System of Georgia Faculty Council (Elected) 2016 – 2017 Member, University System of Georgia Faculty Council (Ex-officio)

• Led this faculty advisory body for the Chancellor of the University System of Georgia • Represented all faculty across the 26 public higher education institutions in Georgia that in 2017-18

enroll 325,203 students as well as conferred 40,533 bachelor’s, 12,176 master’s, 1,791 doctorate, 889 professional degrees

• Reviewed and provided input into board of regents and faculty handbook proposals dealing with a myriad of faculty related issues including appointment, promotion, tenure as well as curriculum policies

• Launched initiatives that bolstered faculty engagement at the USG level leading to increased productive faculty input on a multitude of state entities weighing higher educational issues

UNIVERSITY COMMITTEES University of Georgia 2020 – 2023 Member, President’s Faculty Advisory Committee (Elected) 2018 – 2019 Member, University Comprehensive Administrative Review Working Committee

(President Appointed) • This committee was tasked with finding efficiencies that generate cost savings that can be reinvested

into the institution’s tripartite teaching, research, and service mission, > $2 M in identified savings • Serving as point person on CAR related items dealing with the research enterprise


18

2018 – 2018 Chair, Committee on Statutes, Bylaws, and Committees • Engineered a set of successfully passed University Council statues and bylaw revisions which evolve

them to reflect the diverse set of faculty types that has made UGA a top tier public university

2017 – 2018 Chair, Executive Committee, University Council (Elected) • Led this senatorial model committee representing the faculty, staff, students of the 17 schools and

colleges that served as the final vetting point for items on the general agenda. • Considers and reports on issues affecting the general welfare of the university • Faculty representative for the 3,060 faculty at the University of Georgia, 13th on the U.S. News and

World Report 2018 Top 20 Public National Universities • Part of the University of Georgia’s Spring momentum year team, an USG initiative to increase first

year retention rates at USG institutions

2016 – 2017 Chair Elect, Executive Committee, University Council (Elected) 2015 – 2016 Member, Executive Committee, University Council (Elected) 2014 – 2016 Member, Graduate Council, University of Georgia

• Reviewed and approved graduate faculty status applications • Participated in forming initiative to streamline graduate faculty status applications • Served on graduate curriculum subcommittee responsible for approving new graduate level courses

University of Denver 2013 – 2014 Senator, University Senate Chemistry and Biochemistry (Elected) 2013 – 2014 Member, University Senate Student Relations Committee 2012 – 2014 Member, Sponsored Programs Academic Research Council

• Faculty advisory council to the Vice Provost of Research for university-wide policies to enhance research and research compliance

2012 – 2014 Member, Patent and Intellectual Property Committee • University-wide committee on intellectual property transfer policies, MOUs, and MTAs • Guide the Vice Provost of Research in expenditures related to obtaining, and maintaining, patents

COLLEGE COMMITTEES College of Pharmacy, University of Georgia

2020 – Pres. Academic Operations Committee 2018 – 2021 PharmD Academic and Professionalism Committee 2015 – 2016 Member, Strategic Plan Review and Revision Task Force 2014 – 2016 Member, College of Pharmacy Graduate Education and Curriculum 2016 – 2016 Search Committee for Administration Lead on Grants Management

Natural Sciences and Mathematics, University of Denver

2012 – 2014 Member, High Performance Computing Users Steering Committee 2009 – 2014 Member, Molecular and Cellular Biophysics program

DEPARTMENTAL COMMITTEES University of Georgia

2018 – Present Member, Executive Committee 2017 – 2019 Member, Research Committee 2019 Chair, Post-Tenure Review Committee 2018 – 2019 Member, College of Pharmacy – Center for Tropical and Emerging Global Diseases Joint Faculty

Search Committee (Successful Recruitment of a top tier candidate) 2018 – 2019 Initiator and member of recruitment team eminent faculty member hire 2014 – 2017 Member, Executive Committee 2014 – 2017 Chair, Social Committee


19

2015 Member, Post-Tenure Review Committee 2015 Member, 3rd Year Review Committee of an Assistant Professor 2015 Member, Faculty Search Committee (Successful Hire)

University of Denver

2009 – 2014 Member, Undergraduate Committee 2012, 2013 Member, Faculty Search Committee (Successful Hires) 2009 – 2014 Undergraduate Advisor

OTHER SELECT ADMINISTRATIVE AND LEADERSHIP EXPERIENCE U.S. Armed Forces (1995-present; Current Rank Major U.S. Army Reserve) 2016 – Present Science and Technology Advisor for U.S. Medical Research Institute of Chemical Defense

• Spearheading U.S. Army efforts to leverage structural biology advancements at Brookhaven National Laboratory to accelerate the development of medical therapeutics

• Serving as a liaison between this institute and the Edgewood Chemical and Biology Center to foster research synergy on medical countermeasures for CBRNE threats

2013 – 2016 Science and Technology Advisor for U.S. Army Research, Development and Engineering Command

• Advisor to the Joint US Army and Georgia National Guard Exercise Sudden Response that highlighted methodology and technological improvements to improve WMD response

• Co-led an advisory team to Joint United States - Australia Talisman Sabre Exercise highlighting future technological needs for the U.S. Army fighting in the Pacific garnering General Officer recognition

• Advisor to 2015 Deep Future Wargame event contributing to the future direction of Army research, development, and force structure

2007 – 2009 Company Commander, 244th AVN BDE HHC, Fort Sheridan, IL • Charged with leading, developing, and transitioning of the 35 officers / 91 enlisted Soldiers of the

Headquarters Company of a USAR Aviation Brigade (only one at the time). • Planned, executed, and supervised the BRAC directed relocation of this unit with actively units in the

combat theater from Fort Sheridan, IL to Fort Dix, NJ • Managed >$ 9 M in assets

2004 – 2006 Company Commander, 729th Adjutant General Company Postal • Charged with leading, developing, and preparing a 71 strong U.S. Army Reserve Company • Managed >$4 M in assets, led loss investigations that reduced battle losses from $930 K to $22 K • Launched initiatives that significantly reduced delinquencies in performance evaluation completion,

training, resources, etc. 2003 – 2004 Executive Officer, 729th AG Company Postal Forward, Baghdad, Iraq

• Developed, implemented and supervised an operation that included 7 sites (oversaw construction of three sites), delivery of >15 M lbs. of mail and processing >$2 M in financial transactions for >54,000 U.S. Personnel in the Baghdad Area of Responsibility (AOR)

• Acting Commander for >35 days • Integrated in Baghdad the 131 Soldiers from six USAR platoons and 1 active Army Platoon in from

different parts of the country into one cohesive operational force • Directly responsible for managing >$5.4 M in assets • Unit awarded the Meritorious Unit Citation.

Organization of Meetings • Co-organizer, University System of Georgia Faculty Committee Fall 2018; Spring 2019 Meetings • Co-organizer, Southern Translational Education and Research Conference, September 22-23, 2016 at

the University of Georgia Conference Center Civic Service


20

2012 – 2014 Treasurer, Dam West Subdivision, Aurora, CO • Responsible for budget creation, management, and reserve asset management for a 327-home

subdivision with an annual budget of ~$450 K • Launched and completed capital improvement funding project to ensure the future financial security of

this 1st HOA in the State of Colorado incorporated in 1968 • Negotiated MOU, MOA, and property use licenses with neighboring committees and municipalities.

OTHER SELECT CIVIC OUTREACH

2011 United States Army consultant to the Special Pathogens Branch, Centers for Disease Control and Prevention

2010 Chemical, biological, radiological, and nuclear (CBRNE) Instructor Fort McCoy 2010 White Cell (CBRNE Subject Matter Expert) for “Red Dragon” a joint homeland defense exercise

between United States Army Reserve and local governments

HONORS AND RECOGNITIONS Academic and Research

2021 Recognized by UGA as an Outstanding Teacher in Pharmacy in 2020 in conjunction with a 2020 Teaching Excellence in the College of Pharmacy Award.

2019 Recognized/Coined, Epimilitaris 2019 for contributions to dealing with CBRNE threats 2017 Outstanding Achievement in Invention and Innovation, Center for Disease Control & Prevention 2015 Invited Panelist of Global Youth Health Summit 2015, Emory University 2015 Externally selected as 1 of 170 nation-wide nominees for the Defense Science Study Group 2011-2014 Selected to be the Univ. of Denver Early Career Reviewer for National Institutes of Health 2006 Kamen Award for outstanding dissertation in biology & chemistry, UC San Diego 2006 Travel Scholarship & Conference Poster Winner Keystone Symposia Structural Biology Meeting,

Linking Cardiac Arrhythmia to Gene Defects 2003-2006 Competitive Recipient of NIH Training Grant on Molecular Biophysics Training

Civic Contributions through the U.S. Armed Forces • Meritorious Service Medal (with 1st Oak Leaf Cluster) • Army Commendation Medal (with 1st Oak Leaf Cluster) • Army Achievement Medal (with 1st Oak Leaf Cluster) • Armed Forces Reserve Medal (with Hourglass and M-device) • Army Reserve Components Achievement Medal (with 2 Oak Leaf Cluster) • National Defense Service Medal • Global War on Terror (GWOT) Expeditionary Service Medal • Army Service Ribbon • Army Reserve Component Overseas Training Ribbon (with Numeral 5) • Meritorious Unit Citation • Commandant’s List for Officer Basic, Captain’s Career, and CGSC Common Core Courses

scott d. pegan, ph.d. - profiles.ucr.edu

Documents